People based in United States
| Name | Biography |
|---|---|
| Mr Stephen Stonberg | -- |
| Mr Talmai Morgan | Mr Talmai Morgan is Board Member at BH Global Ltd. Prior to that Mr Morgan was also Board Member at BH Macro Ltd between 01 January 2007 and 26 June 2015. |
| Mr Christopher Legge | -- |
| Mr Anthony Hall | -- |
| Mr Huw Evans | -- |
| Mr Najib Ghauri | Mr Najib Ghauri is Chairman of Netsol Technologies Inc. |
| Mr Michael Splinter | -- |
| Mr James Riepe | -- |
| Mr John Markes | -- |
| Mr Robert Greifeld | -- |
| Mr Borje E. Ekholm | Mr Borje E. Ekholm is a member of board of directors at Alibaba Group Holding Ltd since June 2015. Mr Borje Ekholm was Board Member at Nasdaq OMX Group Inc. |
| Mr Abdul Rahman Abdullah Al Kahwagy | -- |
| Mr Tarek Qassim Fakhro | -- |
| Mr Khaled Rashid Al Thani | -- |
| Mr Suleiman Hamad Al Dalali | -- |
| Mr Mohamed Abdulrahman Al Aflaek | -- |
| Mr M. Farese | Mr. Farese became a director of the Company in August 1998. Mr. Farese is currently President of Chelsea Partners, a firm which he founded in 2004 that specializes in facilitating private investments in privately held companies. For the thirteen years prior to the establishment of Chelsea Investments, Mr. Farese was employed by Filtertek, Inc., an ESCO technology company, most recently holding the position of Business Unit Director. Until February 2010 he was the Chief Executive Officer of Memacin, a firm the he co-found in 2007 that specializes in the manufacture and distribution of dietary supplements and nutraceuticals. Mr. Farese’s extensive knowledge of the Company, his many years’ experience managing high technology businesses that face the same financial and technical challenges as the Company and his experience in the private investment market make him a valuable member of the Board. |
| Mr Michael Cronin | 0 |
| Mr Andrew Cheng | Dr. Cheng joined Gilead Sciences in 1999 and was appointed to his current role of Executive Vice President, Clinical Research and Development Operations in January 2015. In this role, he is responsible for clinical development for the company’s development-stage programs in HIV/AIDS. He also oversees Gilead’s biometrics, clinical operations, clinical pharmacology, drug safety and public health, project management and regulatory affairs activities. Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles.Dr. Cheng is a member of the board of the Global Virus Network, based in Baltimore, Maryland. He received his bachelor’s degree from the Johns Hopkins University and his medical degree and PhD in Cellular and Molecular Biology from Columbia University |
| Mr Meyer Frucher | Meyer “Sandy” Frucher, age 64, has been a director of Reis since June 2000. Mr. Frucher has served as vice chairman of The Nasdaq OMX Group since July 2008. He served as chairman and chief executive officer of the Philadelphia Stock Exchange from June 1998 through the acquisition of the Philadelphia Stock Exchange by The Nasdaq OMX Group in July 2008. From September 1997 through July 2008, Mr. Frucher also served on the Philadelphia Stock Exchange’s board of governors. From 1988 to 1997, Mr. Frucher was executive vice president-development of Olympia & York Companies (U.S.A.) and coordinated and oversaw all of Olympia & York’s development projects in the United States. From 1988 to 1999, Mr. Frucher was trustee and then chairman of the New York City School Construction Authority. From 1984 to 1988, he was president and chief executive officer of the Battery Park City Authority. Mr. Frucher serves on the board of The Options Clearing Corporation, the Saratoga Performing Arts Center, the PHLX Foundation and the Battery Park Conservancy. |
